IMPAX LABORATORIES INC's ticker is IPXL and the CUSIP is 45256B101. A total of 159 filers reported holding IMPAX LABORATORIES INC in Q3 2013. The put-call ratio across all filers is 0.27 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $19,000 | -91.8% | 1,131 | -90.1% | 0.00% | -100.0% |
| Q3 2017 | $231,000 | -68.0% | 11,403 | -80.0% | 0.00% | -75.0% |
| Q1 2017 | $721,000 | +2673.1% | 57,013 | +2766.4% | 0.01% | – |
| Q4 2016 | $26,000 | -87.8% | 1,989 | -73.1% | 0.00% | -100.0% |
| Q2 2016 | $213,000 | +12.7% | 7,383 | +24.9% | 0.00% | 0.0% |
| Q1 2016 | $189,000 | +1081.2% | 5,912 | +1528.7% | 0.00% | – |
| Q4 2015 | $16,000 | -96.9% | 363 | -96.8% | 0.00% | -100.0% |
| Q2 2015 | $519,000 | -51.4% | 11,306 | -50.4% | 0.01% | -58.8% |
| Q1 2015 | $1,068,000 | +747.6% | 22,784 | +440.4% | 0.02% | +750.0% |
| Q2 2014 | $126,000 | -78.2% | 4,216 | -80.7% | 0.00% | -80.0% |
| Q1 2014 | $577,000 | +19133.3% | 21,830 | +18244.5% | 0.01% | – |
| Q4 2013 | $3,000 | -98.6% | 119 | -98.9% | 0.00% | -100.0% |
| Q3 2013 | $215,000 | -21.5% | 10,506 | -23.6% | 0.00% | -42.9% |
| Q2 2013 | $274,000 | – | 13,750 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 423,161 | $13,406,000 | 7.47% |
| Aravt Global | 2,300,000 | $72,864,000 | 5.43% |
| Slate Path Capital LP | 2,330,000 | $73,814,000 | 5.16% |
| Orbimed Advisors | 6,678,000 | $211,559,000 | 2.02% |
| Iguana Healthcare Management, LLC | 100,000 | $3,168,000 | 1.53% |
| Iguana Healthcare Management, LLC | 100,000 | $3,168,000 | 1.53% |
| Penn Capital Management Company, LLC | 709,045 | $22,463,000 | 0.94% |
| HUSSMAN STRATEGIC ADVISORS, INC. | 250,000 | $7,920,000 | 0.79% |
| NEW AMSTERDAM PARTNERS LLC/NY | 276,169 | $8,749,000 | 0.76% |
| Matarin Capital Management, LLC | 52,932 | $1,676,886,000 | 0.74% |